Table 1

Activity of immune checkpoint inhibitor in second-line non-small cell lung cancer (NSCLC)

Squamous NSCLC
Clinical trialCheckMate 01714 KEYNOTE-01011 OAK16
DrugNivolumabDocetaxelPembolizumab*
2–10 mg/kg
DocetaxelAtezolizumabDocetaxel
No. of patients13513715666112110
m OS9.26.0NANA8.97.7
HR0.62 (0.48–0.81)0.74 (0.50–1.09)0.73 (0.54–0.98)
1-year overall survival (OS) (%)422443/52**3555§41§
2-year OS (%)231530.1a/ 37.5b§14.531§21§
3-year OS (%)166